Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Core Insights - Pharvaris is advancing its late-stage development of deucrictibant, an oral bradykinin B2 receptor antagonist aimed at treating hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][10] - Recent presentations at the AAAAI/WAO Joint Congress highlighted positive safety and efficacy data from pivotal Phase 3 studies, indicating a median of zero days with attack symptoms per month for participants on long-term prophylactic treatment [2][4] Prophylactic Program - The CHAPTER-1 Open-Label Extension study involved 30 participants receiving deucrictibant 40 mg/day for an average of 12.8 months, with a maximum exposure of 20.8 months [3] - Participants in the OLE experienced sustained protection from HAE attacks, with a median proportion of days with symptoms being zero each month [4][6] - Health-related quality of life (HRQoL) measures showed significant improvements, particularly in "functioning" and "fear/shame" domains [5][6] On-Demand Program - The RAPIDe-2 extension study evaluated the long-term safety and efficacy of deucrictibant for on-demand treatment of HAE attacks, with data from 337 attacks, including seven upper airway attacks [7] - The median time to onset of symptom relief was 0.9 hours for upper airway attacks, consistent with 1.1 hours for non-airway attacks [7][6] - Deucrictibant was well-tolerated in both extension studies, with no safety signals observed [6][7] Product Overview - Deucrictibant is being developed in two formulations: an extended-release tablet for prophylactic treatment and an immediate-release capsule for on-demand treatment [9][10] - The company aims to provide injectable-like efficacy with the convenience of an oral therapy for HAE attacks [10]